MARSfarm

Origin: MO | Grant Awarded: 2022 | Status: Active

Visit Website →

What is MARSfarm?

There is a technological revolution occurring in the agricultural industry to ensure that humans will be able to sustainably feed our growing population in a changing climate. For over a century, U.S. farmers have learned the technical skills they need from vocational programs in secondary schools. Teachers working in these agriculture programs are desperate to bridge the growing disconnect between the technology being used in the industry and what is accessible to them.

MARSfarm brings ag-tech into the classroom by providing a platform for agricultural educators to give students early exposure to emerging industry practices and problems. Countertop-sized greenhouses designed for the classroom are the enabling hardware of this platform. Our software provides the ability to execute control sequences (called “recipes”) in these greenhouses and remotely monitor them. Consumable kits consisting of seeds, fertilizer, etc. are paired with “recipes” designed in partnership with pioneers of emerging agricultural technologies. This combination of equipment, software, and consumables will ensure that educators are always teaching industry-relevant skills that lead to valuable career education.

Company Leadership

Peter Webb

cEO

Peter Webb began his career working first as a database administrator and then in a business development role at Hussmann Corporation. Peter has also consulted for The Open Agriculture Initiative at the MIT Media Lab and served as the Director of Indoor Farming at The Yield Lab Institute where he mentored several startups in the IN2 program.

Connect on LinkedIn →

Drew Thomas

coO

Drew Thomas comes from a background in engineering, manufacturing, and career technical education. After experiencing CTE training firsthand at Ranken Technical College, he spent his career programming CNC machines to serve the aerospace industry. This led to consulting opportunities for Quip and a teaching position at TechShop, a maker-space formerly in Cortex.

Connect on LinkedIn →

Preventogen

Origin: MO | Grant Awarded: 2021 | Status: Active

Visit Website →

What is Preventogen?

Prevent-Plus has just recently launched a groundbreaking technology into the medical and retail segments. Developed by a NASA Polymer Scientist and a world renowned Dermatologist from NYU, this new advanced infection prevention technology is a non-antibiotic, microbicidal liquid polymer that forms a protective film barrier over the skin. The microbicidal agent in the polymer kills microbes (bacteria, fungi and viruses) on contact, and then forms a flexible, organic, odorless and biodegradable barrier that protects the wound from harmful elements, such as water, dirt and germs. This flexible protective barrier also prevents oxygen entering the wound, lowering the pH and creating an optimal healing environment. This polymer contains NO antibiotics, which puts this technology in a whole new class of advanced infection prevention and wound healing. In a recently published prospective, randomized clinical study, the results were outstanding in the reduction of pin site infections in orthopedic trauma applications: – For patient-level analysis, 33.3% of patients in the control group experienced infection, while none of the patients in the PREVENTOGEN group experienced infection (0%) – For pin-level analysis, 23.3% were infected in the control group, while none (0%) were infected in the PREVENTOGEN group – The application of the PREVENTOGEN liquid polymer has shown its effectiveness in dramatically reducing the rate of pin-tract infections related to external fixation procedure With these new data, Prevent Plus is continuing to build evidence of this polymer’s potential as a new class of transformative therapeutic to prevent infection in areas with high un-met clinical need. Prevent Plus currently has two brands in the marketplace: PREVENTOGEN www.preventogen.com and DuraDerm SPORT www.duradermsport.com and are looking to expand their portfolio into animal health, acne treatment and environmental sterilization and decontamination.

Company Leadership

brad chartrand

ceo

Brad Chartrand is the Chief Executive Officer for parent company Prevent Plus and is responsible for Global growth of the Preventogen and DuraDerm SPORT. Mr. Chartrand has over 15 years of Medical Device experience in various Sales and Marketing leadership roles with Applied Medical, CR BARD and AngioDynamics. Prior to Mr. Chartrand’s Medical Device career, he played 8 years of professional hockey, spending five seasons with the Los Angeles Kings (NHL).

Connect on LinkedIn →

joe thomure

Chairman

Joe Thomure is the Chairman and Managing Member of Prevent Plus and stepped out of retirement in 2018 due to his passion and earnest belief in Preventogen. A graduate of the U.S Merchant Marine Academy in Kings Point, New York, Mr. Thomure was called to active duty in the U.S. Navy, during which time he was promoted twice in three years, and eventually received his honorable discharge, pending LCDR in 1977.

Connect on LinkedIn →

Julie Morris

vice president of clinical research and product development

Julie Morris is the Vice President of Clinical Research and Product Development for Preventogen. Her responsibilities include KOL development and clinical studies. Julie has over 19 years of medical device experience including positions with Covidien, Medtronic, Smith & Nephew and various early stage start-ups where she demonstrated success in several commercial roles. Julie works with our KOL team on the advancement of Preventogen’s clinical research and data and has been a key driver for the advancement of infection prevention in wound care.

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

Drug Design Methodologies

Origin: MO | Grant Awarded: 2017 | Status: Active

Visit Website →

What is Drug Design Methodologies?

Drug Design Methodologies develops novel software to chemically optimize and accurately measure drug-target binding. By identifying and focusing resources upon the most promising candidates and eliminating problematic compounds that could exhibit off-target effects, we accelerate and de-risk drug development pipelines in both pharmaceutical and biotechnology industries while significantly lowering costs.

Company Leadership

Chris Ho

Owner

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

Omniose Logo

Omniose

Origin: MO | Grant Awarded: 2017 | Status: Active

Visit Website →

What is Omniose?

Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform.

They are expanding the range of bacterial targets that can be addressed with bioconjugate vaccines. Bioconjugation relies on single cells that simultaneously produce a polysaccharide antigen along with an engineered carrier protein and a conjugating enzyme to precisely link them together. This is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality vaccines. However, the enzymes used for bioconjugation thus far could only address a limited range of bacterial targets.

Their platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide (sugar) antigen to engineered carrier proteins within a single E. coli cell. Hence the name Omniose, “all sugars.”

Company Leadership

Christian Harding

Co-Founder and Chief Scientific Officer

Dr. Harding is the primary innovator and driver behind Omniose’s R&D activity and bioconjugation platform development. For more than five years, Dr. Harding has helped refine Omniose’s bioconjugation platform for use in developing bioconjugate vaccines against different bacterial threats. He has been awarded multiple federally funded SBIR and STTR grants, authored numerous peer-reviewed manuscripts in distinguished journals, and is the inventor of multiple issued Omniose patents.

Dr. Harding conducted his Postdoctoral Fellowship under Dr. Mario Feldman’s mentorship at Washington University in St. Louis focusing on microbial glycobiology. He earned his Ph.D. in Biomedical Sciences from The Ohio State University and a B.S. from the College of Charleston in Charleston, South Carolina.

Connect on LinkedIn →

Christine Szymanski

co-founder

Dr. Szymanski is a Professor at the Complex Carbohydrate Research Center and Associate Department Head of Microbiology at the University of Georgia. She has been exploring bacterial glycomics for three decades. She combines her expertise in food safety and animal health with novel therapeutic diagnostic platforms developed during her postdoctoral fellowship at the Naval Medical Research Center vaccine program, the key findings while employed at the National Research Council of Canada, and the translational advances during her tenure as an Alberta Innovates Technology Futures Scholar at the University of Alberta where she cofounded VaxAlta, a company creating glycoconjugate vaccines for livestock and human health applications.

Dr. Szymanski has published over 100 publications and has served as President of the Society for Glycobiology and President of the Canadian Society of Microbiologists. She is a Fellow of the American Academy of Microbiology and has received the Peter Gallagher Memorial Glycomics Award for Contributions to Health and Medical Research.

Connect on LinkedIn →

Roman Fleck, Ph.D., MBA

Chairperson

Dr. Fleck is the CEO of Janpix, which was recently merged into Centessa Pharmaceutical. He was previously a Venture Partner/Advisor to Medicxi after having been a Principal at Index Ventures Life Sciences, Medicxi’s predecessor company. He invested in and represented Index Ventures on the boards of GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS), and Novocure (NASDQ: NVCR). Earlier at Index Ventures he was also involved with Funxional Therapeutics (sold to Boehringer Ingelheim) and Micromet (sold to Amgen). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he led drug development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage.

Dr. Fleck received a Ph.D. in bioorganic chemistry from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as many issued patents.

Mario Feldman

Co-Founder & Scientific Advisory Board Member

Mario F. Feldman is a Professor of Molecular Microbiology in the Department of Molecular Microbiology at Washington University School of Medicine, in St Louis. He graduated with a B.S. in Biotechnology from the National University of Rosario, Argentina and received a Ph.D. from the University of Buenos Aires, Argentina. He then held postdoctoral positions at the University of Basel and the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. Before joining Washington University, he was an Associate Professor at the University of Alberta, Canada, where he cofounded VaxAlta, a spin-off company dedicated to livestock vaccines. Dr. Feldman’s current research focuses on the pathogenesis of the multi-drug resistant bacterium Acinetobacter baumannii. He is recognized for his work characterizing secretion systems, microbial glycans, and outer membrane vesicles. He has coauthored over 80 publications in prestigious journals and he has been awarded with multiple NIH grants.

Dr. Feldman is a Fellow of the American Academy of Microbiology. He received the Canadian Institute of Health New Investigator Award.

Timothy Cooke, Ph.D., MBA

Chief Executive Officer

Dr. Cooke has over thirty years of experience in the biopharmaceutical industry with a focus on vaccines. He was previously CEO of NovaDigm Therapeutics, CEO of Mojave Therapeutics, COO at AVANT Immunotherapeutics, and SVP at Ology Bioservices. Prior to his leadership roles in the biotechnology industry, he held several positions at Merck establishing a global vaccine-focused marketing and sales organization.

Dr. Cooke has been the Biotechnology Industry Representative to the U.S. National Vaccine Advisory Committee since 2015. He is on the Advisory Board of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and is an observer on the WHO Technical Advisory Group on Vaccines and Antimicrobial Resistance. He was previously Co-Chair of the BIO Vaccine Policy Advisory Committee and was on the Incentives for Vaccines Working Group of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Dr. Cooke was the Vaccine Industry Representative to the Working Group of Gavi, the Vaccine Alliance during its formation in 2000.

Dr. Cooke has a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University and a B.S. from Saint Joseph’s University.

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

Radiologics

Origin: MO | Grant Awarded: 2016 | Status: Acquired

Visit Website →

What was Radiologics?

Radiologics developed FDA-compliant data management systems for medical imaging in clinical trials.

Radiologics was acquired by Flywheel Exchange in 2021.

Company Leadership

Daniel Marcus

President

Daniel has a B.S. in Biology and a PhD in Neuroscience from Washington University in St. Louis. Daniel is also an Associate Professor at Mallinckrodt Institute of Radiology Washington University, and Director of the Neuroinformatics Research Group.

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

Upaya Pharmaceuticals

Origin: MO | Grant Awarded: Re-Plant | Status: Replant

Visit Website →

What is Upaya Pharmaceuticals?

Upaya Pharmaceuticals, LLC is a biotechnology company inspired to solve important health challenges through the synergy of innovative research and real world applications. The first application developed using our Apollo Technology, allows decreased use of antibiotics and combats antibiotic resistant bacteria.

Company Leadership

Mohit Patel

Founder

Mohit holds a Masters in Biotechnology and Biochemistry from University of Missouri- St. Louis. Before Founding Upaya, Mohit worked with University of Missouri – St. Louis as a Research Assistant.

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

MagBiosense

Origin: MO | Grant Awarded: 2013 | Status: Active

Visit Website →

What is MagBiosense?

MagBiosense is a biotechnology platform developed to commercialize a novel cardiac biomarker diagnostic technology that brings lab-quality, high-sensitivity detection to the point-of-care. The device will change how heart attacks are diagnosed in the Emergency Department by providing high-sensitivity detection of cardiac troponin I.

Company Leadership

Amos Danielli

Founder

Amos earned his degree in Electrical Engineering from Tel Aviv University in 1997, and holds both a Masters and PhD in Physical-Electronics from Tel Aviv University. Amos worked with Washington University in St. Louis and Helioris Solar Systems before joining MagBiosense.

Connect on LinkedIn →

Jasenka Verbarg

Senior Scientist

Jasenka earned her degree in Biomedical Engineering from Saint Louis University in 2006, and holds a PhD in Biological Engineering from University of Missouri-Columbia. Before joining MagBiosense, Jasenka worked with the Naval Research Laboratory and the University of Missouri.

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

Immunophotonics

Origin: MO | Grant Awarded: 2013 | Status: Active

Visit Website →

What is Immunophotonics?

Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology™. IP-001, the first asset from the company’s intellectual property platform, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific anticancer immune response in multiple solid tumor indications. The company is in phase 2 development and is based in St. Louis, Missouri, USA with subsidiaries in Bern, Switzerland and Tianjin, China.

Company Leadership

Lu Alleruzzo

President

Lu earned his degree in Biological/Biomedical Engineering from University of Missouri-Columbia, and holds an MBA from the University of Missouri-Columbia. Lu brings experience working with Dalton Cardiovascular Research Center and the University of Missouri to his position with Immunophotonics.

Connect on LinkedIn →

Tomas Hode

Chief innovation officer & President

Tomas holds a PhD in Astrobiology from Stockholm University, and brings experience working as a researcher with Portland State University to his position with Immunophotonics. Tomas also serves on the Board of Directors of Irradia.

Samuel Lam

Vice President of Research & Science

He earned his degree in Molecular and Cellular Biology from Johns Hopkins University, and holds a degree in Immunology from Washington University in St. Louis. His research has been focused on tumor immunology and tumor vaccine development, and he previously worked at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Medical Center on the development of whole cell tumor vaccines. He has also worked as Immunoassay Scientist at the The Center for Human Immunology and Immunotherapy Programs (CHiiPs) of Washington University School of Medicine.

Theresa Visarius

vice president business development

She holds a PhD in Pharmacology from Switzerland, degrees in biology and chemistry from the USA, and has conducted biochemistry, molecular toxicology, as well as cancer research. She applies her competencies to direct pre-clinical and clinical research, takes on active roles in facilitating market access of innovative medical technologies, in Health Technology Assessment, supplies evidence based creative intelligence, guides publications in the life sciences, serves as scientific advisor and editor, and moderates scientific meetings.

Connect on LinkedIn →

Joseph Raker

senior vp of cmc

Joseph Raker is the Chief Drug Development Officer of Immunophotonics, a 2013 Arch Grants recipient.

Dr. Raker is a fully trained synthetic organic/medicinal chemist with 15+ years experience in the pharmaceutical industry. He was previously responsible for multiple GMP/CMC projects at Kinentia Biosciences and AMRI Burlington and has extensive experience leading international medicinal chemistry teams for a variety of disease indications. He has significant experience and expertise in sterile fill finish process development, analytical method development, program management, and regulatory/compliance oversight. Dr. Raker received a B.S. in chemistry from Utica College of Syracuse University and his Ph.D. in organic chemistry from The Pennsylvania State University.

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.

Adarza BioSystems

Origin: MO | Grant Awarded: 2013 | Status: Active

Visit Website →

What is Adarza BioSystems?

Adarza Biosystems is the developer of a biological assay platform intended to measure clinical and point-of-care samples. The company’s label-free diagnostic platform is capable of simultaneous detection of hundreds of analytes in a single drop of fluid; enabling highly multiplexed protein detection with high sensitivity and specificity.

Company Leadership

bryan witherbee

president & CEO

Bryan joined Adarza BioSystems in January of 2017 to provide leadership as Adarza transitions from a technology developer to a commercial technology provider. Bryan’s career has spanned scientific, business development, and senior leadership positions in large research institutions and early stage startups in pharma, ag biotech, and life science technologies. He brings many years of experience with a successful track record in developing and commercializing new technologies. Bryan’s career started at Sigma Diagnostics where he developed and commercialized clinical immunoassays and coagulation reagents. Over the next 20 years he held various R&D leadership roles at Monsanto and Pfizer. He most recently served as Scientific Leader within the Genomics Division at Becton Dickinson (BD) where he provided leadership for the successful commercial launch of solutions for NextGen Sequencing and single cell genomics. Prior to that he was CSO at GenCell Biosystems, which was acquired by BD in 2014. His key accomplishments include identification and implementation of microfluidic technologies for molecular biology applications, frozen cell technologies, and various high throughput multiplexing technologies for systems biology. Bryan has a BS in Biochemistry from Truman State University.

Connect on LinkedIn →

Christopher Striemer

Vice President of technology

Chris is a founder and current Vice President of Technology for Adarza, responsible for technology development for the next generation Arrayed Imaging Reflectometry assay system. Pursuing applications relevant to his doctoral experience applying silicon nanostructures in biological applications and alternative energy fields, Chris spent the last 12 years working for university spinout companies that bridge the gap between precisely structured silicon chips and biological environments. He brings a wealth of expertise to Adarza in engineering process development, thin film optics and nanoscale materials. Chris has co-authored over 10 patent applications, has 30 peer-reviewed publications, has been the Principle Investigator on Phase I and II SBIR projects with total funding over $2.5M, and has been invited to present his work on optical biosensing and nanostructured materials at conferences in the U.S. and Europe. He received his PhD in Electrical and Computer Engineering from the University of Rochester.

Connect on LinkedIn →

Involved Industries

Be a Part of the Movement

We champion extraordinary entrepreneurs to create positive change – for St. Louis and for the world. Join us by applying to our Global Startup Competition, becoming a financial supporter, volunteering your time or amplifying our message.